4NUC
Crystal structure of the first bromodomain of human BRD4 in complex with MS435 inhibitor
Summary for 4NUC
Entry DOI | 10.2210/pdb4nuc/pdb |
Related | 4NUD 4NUE |
Descriptor | Bromodomain-containing protein 4, 4-[(E)-(4-hydroxy-3,5-dimethylphenyl)diazenyl]-N-(pyridin-2-yl)benzenesulfonamide, 1,2-ETHANEDIOL, ... (4 entities in total) |
Functional Keywords | transcription factor, transcription |
Biological source | Homo sapiens (human) |
Cellular location | Nucleus: O60885 |
Total number of polymer chains | 1 |
Total formula weight | 15543.88 |
Authors | Plotnikov, A.N.,Joshua, J.,Zhou, M.-M. (deposition date: 2013-12-03, release date: 2014-04-02, Last modification date: 2023-09-20) |
Primary citation | Zhang, G.,Plotnikov, A.N.,Rusinova, E.,Shen, T.,Morohashi, K.,Joshua, J.,Zeng, L.,Mujtaba, S.,Ohlmeyer, M.,Zhou, M.-M. Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains J.Med.Chem., 56:9251-9264, 2013 Cited by PubMed Abstract: BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression. PubMed: 24144283PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.4 Å) |
Structure validation
Download full validation report